PEA-NBOMe

PEA-NBOMe
Clinical data
Other names	NBOMe; NBOMe-PEA; N-(2-Methoxybenzyl)phenethylamine
ATC code	None;
Identifiers
	IUPAC name N-[(2-methoxyphenyl)methyl]-2-phenylethanamine;
CAS Number	3241-03-0;
PubChem CID	1618894;
ChemSpider	1300700;
CompTox Dashboard (EPA)	DTXSID00364619 ;
Chemical and physical data
Formula	C16H19NO
Molar mass	241.334 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC=CC=C1CNCCC2=CC=CC=C2;
	InChI InChI=1S/C16H19NO/c1-18-16-10-6-5-9-15(16)13-17-12-11-14-7-3-2-4-8-14/h2-10,17H,11-13H2,1H3; Key:UTYSBUBGYZSUPZ-UHFFFAOYSA-N;

PEA-NBOMe, also known as N-(2-methoxybenzyl)phenethylamine, is a drug of the phenethylamine and N-benzylphenethylamine (NB; NBOMe) families related to phenethylamine (PEA). It is the N-(2-methoxybenzyl) derivative of phenethylamine. The drug is a parent compound of the NBOMe family of psychedelic drugs, such as 25I-NBOMe. No data on the pharmacology or toxicity of PEA-NBOMe are available. In any case, based on structure–activity relationships, PEA-NBOMe might produce stimulant and/or hallucinogenic effects. The drug was encountered as a novel designer drug online in 2024. It is not a controlled substance in Canada as of 2025.